Joy Meng, MD
Neurology · San Francisco, CANPI 1174786123
Payments from drug & device makers
Across 663 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Arbor Pharmaceuticals, Inc.$1K
- Amneal Pharmaceuticals LLC$720
- Avanir Pharmaceuticals, Inc.$701
- plus $6K from 30 others
What the payments were for
- Speaking & faculty fees$370%
- Food & beverage$14,84497%
- Education$3542%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 141 | $2,764 |
| Teva Pharmaceuticals USA, Inc. | 66 | $2,119 |
| Neurocrine Biosciences, Inc. | 78 | $1,986 |
| Arbor Pharmaceuticals, Inc. | 88 | $1,230 |
| Amneal Pharmaceuticals LLC | 32 | $720 |
| Avanir Pharmaceuticals, Inc. | 23 | $701 |
| MDD US Operations, LLC | 23 | $687 |
| SK Life Science, Inc. | 24 | $571 |
| Pfizer | 28 | $515 |
| Otsuka America Pharmaceutical, Inc. | 17 | $384 |
| Lundbeck LLC | 13 | $346 |
| Biogen | 12 | $280 |
| Kyowa Kirin, Inc. | 12 | $278 |
| Lilly USA, LLC | 9 | $270 |
| Acorda Therapeutics, Inc | 14 | $268 |
| Eisai Inc. | 7 | $258 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $242 |
| GE HealthCare | 9 | $230 |
| Merz Pharmaceuticals, LLC | 5 | $221 |
| Acadia Pharmaceuticals Inc | 8 | $188 |
| Scilex Pharmaceuticals Inc. | 7 | $145 |
| Adamas Pharmaceuticals, Inc. | 5 | $142 |
| UCB, Inc. | 4 | $99 |
| Johnson & Johnson | 1 | $72 |
| Argenx US, Inc. | 2 | $65 |
| Biohaven Pharmaceuticals, Inc. | 3 | $61 |
| Avion Pharmaceuticals | 3 | $59 |
| Amgen(2 entities) | 3 | $56 |
| Almatica Pharma LLC | 2 | $53 |
| Merck | 3 | $52 |
| Cala Health, Inc. | 2 | $49 |
| AstraZeneca | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Grifols USA, LLC | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,235 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 41 | $307,282 |
| Austedo XrDeutetrabenazine | 28 | $288,949 |
| HorizantGabapentin Enacarbil | 81 | $140,078 |
| NeuproRotigotine | 68 | $95,031 |
| RytaryCarbidopa/Levodopa | 57 | $87,848 |
| OngentysOpicapone | 60 | $86,942 |
| NuedextaDextromethorphan Hbr/Quinidine | 35 | $78,546 |
| NourianzIstradefylline | 20 | $68,957 |
| BotoxOnabotulinumtoxina | 50 | $56,831 |
| RexultiBrexpiprazole | 15 | $35,716 |
| Memantine Hcl ErMemantine Hcl | 185 | $34,089 |
| NamzaricMemantine Hcl/Donepezil Hcl | 23 | $31,393 |
| Rasagiline Mesylate | 59 | $21,963 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 368 | $16,657 |
| BelsomraSuvorexant | 22 | $12,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $188 | $307,28241 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,119 | $288,94928 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $1,230 | $140,07881 claims |
| UCB, Inc.Neupro | $99 | $95,03168 claims |
| AbbVieBotox, Namzaric | $2,764 | $88,22473 claims |
| Amneal Pharmaceuticals LLCRytary | $720 | $87,84857 claims |
| Neurocrine Biosciences, Inc.Ongentys | $1,986 | $86,94260 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $701 | $78,54635 claims |
| Kyowa Kirin, Inc.Nourianz | $278 | $68,95720 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $384 | $35,71615 claims |
| MerckBelsomra | $52 | $12,00522 claims |
| Almatica Pharma LLCSertraline Hcl | $53 | $38022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.
Other neurology in San Francisco
- Bruce CreeSan Francisco$8M
- Stanley PrusinerSan Francisco$6.5M
- Adam BoxerSan Francisco$5.5M
- Jennifer ClarkeSan Francisco$5.1M
- Nancy Ann Oberheim BushSan Francisco$4.6M
- Emmanuelle WaubantSan Francisco$3M
- Jill OstremSan Francisco$2M
- William JagustSan Francisco$2M
- Gil RabinoviciSan Francisco$1.9M
- Jonathan KatzSan Francisco$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.